K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $118.81
    +0.66 (+0.56%)

    Market Cap: $9.72B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(9/24)
    Avg Surprise
    -41.35%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.24
    Range$-1.44 - $-0.93
    20 analysts
    EPS Revisions
    2
    0
    7d
    2
    11
    30d
    EPS Estimate Drift
    90d ago$-1.03+17.0%
    60d ago$-1.03+17.1%
    30d ago$-1.03+17.0%
    7d ago$-1.24+0.0%
    Current$-1.24
    Revenue Consensus
    $4M
    Range$-1000000 - $20M
    20 analysts
    Dec 31, 2026
    EPS Consensus$-0.98
    Range$-1.45 - $-0.31
    20 analysts
    Revenue Consensus
    $62M
    Range$52M - $94M
    22 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.98---
    Sep 26EST
    		-$-1.24---
    Jun 26
    		$-0.62$-0.64+3.13%Beat+34.7%
    Mar 26
    		$-0.71$-0.86+17.44%Beat+13.4%
    Dec 25
    		$-0.97$-0.77-25.97%Miss-9.0%
    Sep 25
    		$-0.94$-0.78-20.51%Miss-14.6%
    Jun 25
    		$-0.95$-0.80-18.75%Miss-63.8%
    Mar 25
    		$-0.82$-0.91+9.89%Beat-32.3%
    Dec 24
    		$-0.89$-0.79-12.92%Miss-256.0%
    Sep 24
    		$-0.82$-0.84+2.38%Beat+8.9%
    Jun 24
    		$-0.58$-0.66+12.12%Beat+13.4%
    Mar 24
    		$-0.62$-0.72+13.89%Beat+11.4%
    Dec 23
    		$-0.25$-0.40+37.50%Beat+58.3%
    Sep 23
    		$-0.90$-0.70-28.57%Miss-13.9%
    Jun 23
    		$-0.67$-0.74+9.46%Beat+14.1%
    Mar 23
    		$-0.70$-0.69-1.45%Miss+1.4%
    Dec 22
    		$-0.60$-0.63+4.76%Beat+9.1%
    Sep 22
    		$-0.79$-0.75-5.33%Miss-41.1%
    Jun 22
    		$-0.78$-0.69-13.04%Miss-41.8%
    Mar 22
    		$-0.71$-0.67-5.97%Miss-144.8%
    Dec 21
    		$-0.66$-0.57-15.79%Miss-127.6%
    Sep 21
    		$-0.56$-0.37-51.35%Miss-43.6%
    Jun 21
    		$-0.55$-0.25-120.00%Miss-31.0%
    Mar 21
    		$-0.29$-0.20-45.00%Miss+69.8%
    Dec 20
    		$-0.29$-0.04-625.00%Miss-
    Sep 20
    		$-0.39N/A-113.40%Miss-
    Jun 20
    		$-0.42N/AN/ABeat-
    Mar 20
    		$-0.96$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-36.67EV/EBITDA-9.49x
    Price/FCF-49.02xFCF Yield-2.04%
    Profitability
    Profit Margin-285.30%Operating Margin-116.30%
    ROE-24.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.34xQuick Ratio10.34x
    Trading Statistics
    Beta1.95Avg Volume686.55K
    52-Week High$130.0552-Week Low$39.84

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$122.04
    SMA 20$116.48
    SMA 50$112.89
    SMA 200$88.01
    EMA 10$120.11
    EMA 20$117.61
    EMA 50$110.50
    EMA 200$88.76

    MACD

    Line: 3.54Signal: 3.80Hist: -0.26

    ADX

    ADX: 32.8+DI: 26.5-DI: 20.1

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$127.64

    Bollinger Bands

    Upper Band$130.99
    Lower Band$101.97
    %B Position2491%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    54.3

    Momentum Oscillators

    Stoch %K57.3
    Stoch %D70.2
    Williams %R-48.2
    ROC (10d)-2.1%
    Momentum-2.60
    CCI (20d)23.4
    MFI (14d)56.7

    Volatility Measures

    ATR (14d)$4.98(4.2%)
    StdDev (20d)7.25
    Hist Vol41.8%(High)

    Volume Flow

    VWAP$118.25
    OBV32.9M
    AD Line12.4M
    CMF (20d)0.397

    Volume Metrics

    Avg Vol (20d)687.5K
    Vol Ratio1.0x
    VWMA (20d)$116.18

    Pivot Points

    R3$125.42
    R2$123.70
    R1$120.92
    Pivot Point$119.20
    S1$116.43
    S2$114.71
    S3$111.93

    Advanced Oscillators

    TSI19.43
    Ultimate Osc51.6
    KST101.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M$3.74M$25.65M$10.29M$47.88M$4.73M
    Cost of Revenue$0$0$-76,178,000$0$0$0$1.97M$0$0$0$865,000$0
    Gross Profit$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M$3.74M$25.65M$10.29M$47.88M$4.73M
    Operating Expenses$140.61M$118.52M$100.77M$95.28M$96.03M$96.53M$88.15M$75.86M$76.58M$68.12M$67.20M$62.24M
    R&D$119.48M$98.16M$83.83M$74.09M$78.39M$80.25M$71.82M$60.41M$59.20M$48.82M$52.97M$48.12M
    SG&A$21.13M$20.36M$16.93M$17.34M$17.64M$16.27M$16.33M$15.46M$17.37M$14.37M$14.23M$14.12M
    Operating Income$-75,607,000$-84,154,000$-97,895,000$-92,521,000$-84,557,000$-74,426,000$-80,755,000$-72,124,000$-50,925,000$-57,831,000$-19,312,000$-57,509,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-61,211,000$-69,234,000$-86,981,000$-82,175,000$-76,614,000$-65,581,000$-70,752,000$-62,487,000$-42,062,000$-48,557,000$-14,368,000$-52,867,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-61,211,000$-69,234,000$-86,981,000$-82,175,000$-76,614,000$-65,581,000$-70,752,000$-62,487,000$-42,062,000$-48,557,000$-14,368,000$-52,867,000
    EBITDA$-59,181,000$-67,212,000$-84,949,000$-80,026,000$-74,530,000$-63,533,000$-68,765,000$-60,500,000$-40,124,000$-47,096,000$-13,477,000$-51,972,000
    EBIT$-61,211,000$-69,234,000$-86,981,000$-82,175,000$-76,614,000$-65,581,000$-70,752,000$-62,487,000$-42,062,000$-48,557,000$-14,368,000$-52,867,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KYMR

    News

    Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR

    Nicholas Investment Partners LP has acquired a new stake worth $6.26 million in Kymera Therapeutics, Inc. Other institutional investors like BlackRock and Baker Bros. Advisors have also increased their positions, indicating positive sentiment despite significant insider selling. Analysts maintain a "Moderate Buy" consensus with an average price target of $125.65 for Kymera Therapeutics.

    MarketBeat•8/25/26•
    Bullish

    Nan Fung Group Holdings Ltd Invests $3.54 Billion in Kymera Therapeutics, Inc. $KYMR

    Nan Fung Group Holdings Ltd recently acquired 30,875 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) for approximately $3.54 billion during the second quarter, making it their 11th largest holding. Kymera Therapeutics reported strong quarterly revenue growth of 465.2% year-over-year, beating analyst estimates, and a narrower-than-expected loss per share. Despite significant insider selling in the last quarter, analysts maintain a "Moderate Buy" rating with a consensus price target of $125.65.

    MarketBeat•8/25/26•
    Bullish

    12,083 Shares in Kymera Therapeutics, Inc. $KYMR Bought by B. Metzler seel. Sohn & Co. AG

    B. Metzler seel. Sohn & Co. AG recently acquired 12,083 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, valuing their new stake at approximately $1.386 million. This purchase is part of broader institutional interest, with several other firms increasing their holdings in the company. Kymera Therapeutics reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and analysts currently maintain a "Moderate Buy" consensus rating for the stock.

    MarketBeat•8/24/26•
    Somewhat-Bullish

    5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc.

    BlackRock Inc. recently acquired 5,538,210 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR), valued at approximately $635.1 million, giving it a 6.73% stake in the company. Kymera Therapeutics reported strong quarterly revenue growth of 465.2% year-over-year, beating analyst expectations for both revenue and EPS, despite significant insider stock sales during the quarter. Analysts maintain a "Moderate Buy" rating with a consensus price target of $125.65.

    MarketBeat•8/24/26•
    Neutral

    Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR

    Deutsche Bank AG has made a new investment of $12.16 million in Kymera Therapeutics, Inc. by purchasing 106,049 shares during the second quarter. This move makes Deutsche Bank AG the owner of approximately 0.13% of Kymera Therapeutics' stock. Several other institutional investors have also adjusted their positions in the company, while some insiders have sold shares.

    MarketBeat•8/23/26•
    Bullish

    Frequently Asked Questions About KYMR

    Does KYMR pay dividends?
    Kymera Therapeutics Inc (KYMR) does not currently pay a regular dividend.
    What is KYMR's market cap?
    Kymera Therapeutics Inc (KYMR) has a market capitalization of $9.72B with a current stock price of $118.81.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In